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Trace element selenium (Se) is regarded to be a breast cancer preventive factor involved in multiple protective pathways. In all, 80
women with breast cancer who underwent a radical mastectomy were enrolled in the study. Serum Se and carcinoembryonic antigen
levels were measured using a fluorometric and IRMA assay, respectively. Se tissue concentration was determined by a tissue
extracting fluorometric assay. For statistical analysis purposes t-test was used and P-values o0.001 were regarded as statistically
significant. Serum Se was 42.577.5mgl
 1 in breast cancer patients and 67.675.36mgl
 1 in the age-matched control group of
healthy individuals. Serum carcinoembryonic antigen in patients was 1071.7Uml
 1 (normal o2.5Uml
 1 in nonsmokers/
o3.5Uml
 1 in smokers). A statistically significant difference was found for both serum Se and CEA between two groups studied
(Po0.001). Neoplastic tissue Se concentration was 26607210mgg
 1 tissue; its concentration in the adjacent non-neoplastic tissue
was 6807110mgg
 1 tissue (Po0.001). An inverse relationship between Se and CEA serum levels was found in the two groups
studied (r¼ 0.794). There was no correlation between serum/tissue Se concentration and stage of the disease. The decrease in
serum Se concentration as well as its increased concentration in the neoplastic breast tissue is of great significance. These alterations
may reflect part of the defence mechanisms against the carcinogenetic process.
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Breast cancer is regarded as the third most common malignancy in
humans and the second, after skin cancer, in women (Greenlee
et al, 2000). Approximately, 150000 women in the United States of
America are affected every year (Wolff and Weston, 1997). Much
knowledge has been accumulated on the aetiology and patho-
genesis of this malignancy implicating genetic, hormonal and
environmental factors (Simopoulos, 2004). The influence of
micronutrient status on breast cancer development in humans is,
nowadays, under continuous investigation. It has been postulated
that a high intake of micronutrients in diet may prevent
carcinogenesis (Lianidou et al, 1997; Charalabopoulos et al,
2003). Trace elements play an important role in a number of
biological processes by activating or inhibiting various enzymes
(Garg et al, 1994). Selenium (Se) is an essential nonmetallic trace
element and its plasma and tissue concentration is regulated by
incompletely understood homeostatic mechanisms. Se exists in the
body in the form of selenocystein, a component of selenoproteins
and has important structural and enzymic roles, such as
antioxidant activity (Huang et al, 1999, Rayman, 2000; Rayman,
2005). Cellular oxidative damage is a general mechanism for cell
and tissue injury. Oxidative stress in the target tissue has been
suggested to play an important role in carcinogenic process. Thus,
Se may act as an antitumoural agent although more studies are
needed to investigate the actual role of antioxidants and their
possible relationships with trace elements alterations in the
pathogenesis of breast cancer (Bock et al, 1991; Gerber et al,
1996). Furthermore, it has been shown that Se supplementation
decreases the COX-2 protein and PGE-2 levels in colorectal cancer
cells. In addition, Se exhibits an antiproliferative effect modulating
cellular proliferation in G1 phase in both normal and neoplastic
cells impairing the expression of c-fos and c-myc oncogenes (Kuo
et al, 2002). However, other prospective studies have failed to
confirm these findings (Garland et al, 1995; Ghadirian et al, 2000).
A strong relationship between low-serum Se concentration and
increased risk of breast cancer has been documented (Bratakos
et al, 1990a,b; Mannisto et al, 2000; Kuo et al, 2002; Lopez-Saez
et al, 2003).
The aim of the present study was to determine the levels serum
Se in breast cancer patients and healthy controls and to correlate
them with Se levels in neoplastic tissue.
MATERIALS AND METHODS
In all, 80 women with infiltrative ductal carcinoma (nonspecific
type, stages I–IV) who underwent radical mastectomy, 45710. 6
years old, pre- and postmenopausal, were enrolled in the study.
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sA female aged matched population group (consisting of 250
individuals) was selected for comparison of the laboratory data
(Kallistratos et al, 1985; Charalabopoulos et al, 2006). In patients,
serum Se levels were measured, at the time of diagnosis before any
kind of treatment was started, by the fluorometric method
(Watkinson’s) modified by Thorling. This is a specific and very
sensitive method among others (eg phasmatometric, nonflame
molecular absorption, netronic activation, volumetric method)
detecting Se at a quantity of 0.002mg and is considered the method
of choice throughout Europe (Thorling et al, 1986). Whole blood
(10ml) was taken and centrifuged. The samples were preserved
at –41C. Neoplastic and healthy tissue samples surrounding the
tumour were taken during operation and preserved in liquid N2.
To determine Se tissue concentration, a modified extracting
fluorometric assay, similar to the above described, was used.
Serum CEA levels were measured by IRMA assay, using
commercial kits. For statistical analysis purposes, t-test was used
and P-values o0.001 were regarded as statistically significant.
Table 1 shows laboratory and statistical data of the groups studied.
RESULTS
Serum Se was 42.577.5mgl
 1 in breast cancer patients and
67.675.36mgl
 1 in the age-matched control group of healthy
individuals. Neoplastic tissue Se concentration was
26607210mgg
 1 tissue; its concentration in the adjacent non-
neoplastic tissue was 6807110mgg
 1 tissue. Compared to control
group Se concentration in serum was lower in breast cancer
patients (Po0.001). A statistical significant difference was also
found between Se concentration in neoplastic breast tissue
compared to normal tissue samples surrounding the neoplastic
area; Se levels were almost four-fold higher in neoplastic tissue.
Serum CEA levels in breast cancer patients were 1071.7Uml
 1
(normal o2.5Uml
 1 in nonsmokers/o3.5Uml
 1 in smokers, the
mean concentration in the control group was 2.3Uml
 1). An
inverse relationship between Se and CEA serum levels was found in
the two groups studied (r¼ 0.794). No correlation between
serum/tissue Se concentration and stage of the disease was found.
DISCUSSION
Breast cancer is an important contributor to morbidity and
mortality in humans. Trace element Se has been regarded as a
breast cancer preventive factor (Kallistratos et al, 1989; Medina
et al, 2001). However, in a large study a nonsignificant relationship
between Se supplementation and increased breast cancer risk
was shown (Clark et al, 1996). Se absorption is a complex, poorly
understood process. Studies in rats have provided us with some
information but little is known about this mechanism in humans.
There is a particular Se-containing gene that encodes for Se-
containing proteins and its various polymorphisms may lead to
decreased element absorption (Esworthy et al, 1995). The basal
amount of dietary Se is also debated. Dietary intakes show a large
geographic variation mainly due to differences in Se bioavail-
ability. In Greece the Se concentration in 315 examined foods was
shown to be lower than other European countries and closer to
UK. The daily Se intake of Greeks is estimated to approximately
110mg (Kallistratos et al, 1985; Bratakos et al, 1987; Bratakos et al,
1990b; Charalabopoulos et al, 2006).
Human body Se is incorporated into the polypeptide backbone
of some proteins and through them it regulates the cellular
antioxidant defense system, DNA damage and protein function.
Se also controls cell-mediated immunity and B-cell function. The
lower serum Se levels in cancer patients can be attributed to either
lower Se intake, to sequestration of this element by the tumour
cells or both (Di Ilio et al, 1985; Bratakos et al, 1990a).
To our best knowledge, the present study is the fourth one in the
last 40 years (Pub-Med search) providing information regarding
the neoplastic tissue Se concentration in breast cancer patients and
the first one providing data for serum/tissue Se concentrations
simultaneously, in association with serum CEA levels (Garg et al,
1994; Sharma et al, 1994; Kuo et al, 2002). It is notable that Se
concentration in the neoplastic tissue was nearly fourfold greater
than in the adjacent normal breast tissue. Our findings regarding
serum/tissue Se levels in patients suffering from breast cancer are
in agreement with other reports in patients with lung, gastric,
renal, colorectal and breast cancer, where an increased concentra-
tion of Se in the neoplastic tissue was found (Garg et al, 1994;
Sharma et al, 1994; Burguera et al, 1995; Kuo et al, 2002;
Charalabopoulos et al, 2006).
It is not clear whether the increased Se concentration in the
cancerous tissue is responsible for the decreased serum Se levels
found in these patients or if the decreased serum Se levels precede
the development of breast cancer. Another consideration is the
significance of the increased Se concentration in neoplastic tissue.
An attractive hypothesis is that it is part of the defence
mechanisms against the neoplastic process. This concept is greatly
supported by the already above-mentioned antioxidant action of
Se. The usefulness and the significance of our findings should be
clarified with further future investigation.
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